Regeneron

Regeneron Pharmaceuticals is a pioneering biotechnology company dedicated to inventing and developing life-transforming medicines for individuals facing serious diseases. Founded over 35 years ago and led by a team of physician-scientists, Regeneron integrates cutting-edge scientific research with clinical practice. The company specializes in an extensive range of therapeutic areas, including eye diseases, cancer, allergic and inflammatory conditions, and genetic medicine.

Regeneron's commitment to innovation is exemplified through its proprietary technologies, such as VelociSuite®, which maximizes the effectiveness of fully human antibodies and bispecific antibodies. The company is also at the forefront of genetic medicine, utilizing data-driven insights from the Regeneron Genetics Center® to identify new treatment targets.

With a robust portfolio featuring 12 FDA-approved medicines and approximately 35 product candidates in development, Regeneron is steadfast in its mission to deliver hope and improve lives by tackling some of the world’s toughest health challenges through relentless research and development.